Combination Use of Tegafur and Apatinib as First-Line Therapy in Treatment of Advanced Gastric Cancer: A Single-Blinded Randomized Study

Abstract

Objective. To investigate the efficacy and safety of the combination use of tegafur and apatinib as a first-line therapy strategy in advanced gastric cancer (GC). Methods. The present study included a total of 62 advanced GC patients. The patients were randomized into the combined group (treated with both tegafur and apatinib) and the control group (treated with only tegafur). Treatment efficacy, KPS score, nutrition condition, and progression-free survival time (PFS) were recorded. Results. Both the response and disease control rates were significantly higher in the combined group. The PFS time was remarkably higher and the KPS score was significantly reduced in the combined group after treatment. After treatment, both groups showed significantly increased nutrition risk, but the rates of patients with nutrition risk or innutrition were remarkably higher in the combined group. The ADR rates were also significantly higher in the combined group. Conclusion. The combination use could achieve good efficacy and prolong patients’ PFS time; however, apatinib also reduced the patients’ quality of life and enhanced the nutrition risk and adverse drug reactions.

Comparative efficacy and tolerability of targeted and immunotherapy combined with chemotherapy as first-line treatment for advanced gastric cancer: a Bayesian network meta-analysis

“…One study was excluded because it could not be incorporated into network calculation 17 . Another study was excluded as the chemotherapy regimens did not meet the criteria for the standard first-line chemotherapy in NCCN 2021 guidelines 18 . Two other studies were not included because patients had previously received systemic chemotherapy within 6 months or the time of administration was not clearly indicated 19 , 20 .…”

Clinical progress of anti-angiogenic targeted therapy and combination therapy for gastric cancer

“…Combination therapy with apatinib, especially with paclitaxel, may confer a better survival benefit in the first-line treatment ( 132 ). However, some studies have also suggested that while increasing the curative effect, combined drug use reduced the quality of life of patients and increased the risk of adverse reactions ( 109 ).…”